Skip to main content
Erschienen in: Zeitschrift für Rheumatologie 1/2018

12.09.2016 | Originalien

Urinary TNF-like weak inducer of apoptosis (TWEAK) as a biomarker of lupus nephritis

verfasst von: M. N. Salem, H. A. Taha, M. Abd El-Fattah El-Feqi, N. N. Eesa, R. A. Mohamed

Erschienen in: Zeitschrift für Rheumatologie | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Renal involvement in systemic lupus erythematosus (SLE), known as lupus nephritis (LN), is a common and severe complication and a major predictor of poor outcome. Long-term survival in SLE can be improved with early diagnosis and prompt treatment of LN. A number of biochemical markers are currently used to clinically assess disease activity in patients; however, they lack sensitivity and specificity for differentiating renal activity and damage in LN. A reliable clinical biomarker that can forecast LN flare and which could be sequentially followed would help to optimize initiation and escalation of therapy at the time of active or relapsing disease.

Objective

This study was carried out to investigate the value of urinary tumor necrosis factor (TNF)-like weak inducer of apoptosis (uTWEAK) as a biomarker for active lupus nephritis.

Patients and methods

A total of 44 patients with SLE fulfilling the 1997 revised criteria for the classification of SLE as well as 11 age and sex-matched healthy controls were included in this study and subjected to full medical history taking, clinical examination, routine laboratory investigations, measurement of uTWEAK level as well as renal biopsy for patients with active LN.

Results

The uTWEAK levels were significantly higher in SLE patients with active LN compared to those without or with inactive renal disease and normal healthy subjects.
Fußnoten
1
Spot urine test is a test for proteinuria. Protein-to-creatinine ratio (P/C) in spot urine specimens is a predictor of urine protein excretion in 24-h collections.
 
Literatur
1.
Zurück zum Zitat Illei GG, Lipsky PE (2004) Biomarkers in systemic lupus erythematosus. Curr Rheumatol Rep 6:382–390CrossRefPubMed Illei GG, Lipsky PE (2004) Biomarkers in systemic lupus erythematosus. Curr Rheumatol Rep 6:382–390CrossRefPubMed
2.
Zurück zum Zitat Salgado A, Herrera-Diaz C (2012) Lupus nephritis: an overview of recent findings. Autoimmune Dis 2012:1–21CrossRef Salgado A, Herrera-Diaz C (2012) Lupus nephritis: an overview of recent findings. Autoimmune Dis 2012:1–21CrossRef
3.
Zurück zum Zitat Korbet SM, Lewis EJ, Schwartz MM (2000) Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 35:904–914CrossRefPubMed Korbet SM, Lewis EJ, Schwartz MM (2000) Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 35:904–914CrossRefPubMed
4.
Zurück zum Zitat Esdaile JM, Joseph L, MacKenzie T, Kashgarian M, Hayslett JP (1994) The benefit of early treatment with immunosuppressive agents in lupus nephritis. J Rheumatol 21:2046–2051PubMed Esdaile JM, Joseph L, MacKenzie T, Kashgarian M, Hayslett JP (1994) The benefit of early treatment with immunosuppressive agents in lupus nephritis. J Rheumatol 21:2046–2051PubMed
5.
Zurück zum Zitat Illei GG, Tackey E, Lapteva L, Lipsky PE (2004) Biomarkers in systemic lupus erythematosus: II. Markers of disease activity. Arthritis Rheum 50:2048–2065CrossRefPubMed Illei GG, Tackey E, Lapteva L, Lipsky PE (2004) Biomarkers in systemic lupus erythematosus: II. Markers of disease activity. Arthritis Rheum 50:2048–2065CrossRefPubMed
6.
Zurück zum Zitat Schwartz N, Michaelson JS, Putterman C (2007) Lipocalin-2, TWEAK, and other cytokines as urinary biomarkers for lupus nephritis. Ann NY Acad Sci 1109:265–274CrossRefPubMed Schwartz N, Michaelson JS, Putterman C (2007) Lipocalin-2, TWEAK, and other cytokines as urinary biomarkers for lupus nephritis. Ann NY Acad Sci 1109:265–274CrossRefPubMed
8.
Zurück zum Zitat Fiehn C, Hajjar Y, Mueller K, Waldherr R, Ho AD, Andrassy K (2003) Improved clinical outcome of lupus nephritis during the past decade: Importance of early diagnosis and treatment. Ann Rheum Dis 62:435–439CrossRefPubMedPubMedCentral Fiehn C, Hajjar Y, Mueller K, Waldherr R, Ho AD, Andrassy K (2003) Improved clinical outcome of lupus nephritis during the past decade: Importance of early diagnosis and treatment. Ann Rheum Dis 62:435–439CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, Garrido ER, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gul A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns J‑P, Crevera R (2004) Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis. Arthritis Rheum 50:3934–3940CrossRefPubMed Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, Garrido ER, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gul A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns J‑P, Crevera R (2004) Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis. Arthritis Rheum 50:3934–3940CrossRefPubMed
10.
Zurück zum Zitat Austin HA, Boumpas DT, Vaughan EM, Balow JE (1995) High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 10:1620–1628PubMed Austin HA, Boumpas DT, Vaughan EM, Balow JE (1995) High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 10:1620–1628PubMed
11.
Zurück zum Zitat Schwartz N, Michaelson J, Putterman C (2007) Lipocalin-2,TWEAK, and other cytokines as urinary biomarkers for lupus nephritis. Ann N Y Acad Sci 1109:265–274CrossRefPubMed Schwartz N, Michaelson J, Putterman C (2007) Lipocalin-2,TWEAK, and other cytokines as urinary biomarkers for lupus nephritis. Ann N Y Acad Sci 1109:265–274CrossRefPubMed
12.
Zurück zum Zitat Maecker H, Varfolomeev E, Kischkel F et al (2005) TWEAK attenuates the transition from innate to adaptive immunity. Cell 123:931–944CrossRefPubMed Maecker H, Varfolomeev E, Kischkel F et al (2005) TWEAK attenuates the transition from innate to adaptive immunity. Cell 123:931–944CrossRefPubMed
13.
Zurück zum Zitat Muñoz-García B, Martín-Ventura JL, Martínez E, Sánchez S, Hernández G, Ortega L, Ortiz A, Egido J, Blanco-Colio LM (2006) Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques modulation by atorvastatin. Stroke 37(8):2044–2053CrossRefPubMed Muñoz-García B, Martín-Ventura JL, Martínez E, Sánchez S, Hernández G, Ortega L, Ortiz A, Egido J, Blanco-Colio LM (2006) Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques modulation by atorvastatin. Stroke 37(8):2044–2053CrossRefPubMed
14.
Zurück zum Zitat Sanz AB, Santamaria B, Ruiz Ortega M, Egido J, Ortiz A (2008) Mechanisms of renal apoptosis in health and disease. J Am Soc Nephrol 19(9):695–703CrossRefPubMedPubMedCentral Sanz AB, Santamaria B, Ruiz Ortega M, Egido J, Ortiz A (2008) Mechanisms of renal apoptosis in health and disease. J Am Soc Nephrol 19(9):695–703CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Burkly LC, Michaelson JS, Hahm K, Zheng TS (2007) TWEAKing tissue remodeling by a multifunctional cytokine: Role of TWEAK/Fn14 pathway in health and disease. Cytokine 40(1):1–16CrossRefPubMed Burkly LC, Michaelson JS, Hahm K, Zheng TS (2007) TWEAKing tissue remodeling by a multifunctional cytokine: Role of TWEAK/Fn14 pathway in health and disease. Cytokine 40(1):1–16CrossRefPubMed
16.
17.
Zurück zum Zitat Gao HX, Campbell SR, Burkly LC, Jakubowski A, Jarchum I, Banas B et al (2009) TNFlike weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cells. Cytokines 46:24e35CrossRef Gao HX, Campbell SR, Burkly LC, Jakubowski A, Jarchum I, Banas B et al (2009) TNFlike weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cells. Cytokines 46:24e35CrossRef
18.
Zurück zum Zitat Zhao Z, Burkly LC, Campbell S, Schwartz N, Molano A, Choudhury A, Eisenberg RA, Michaelson JS, Putterman C (2007) TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J Immunol 179:7949–7958CrossRefPubMed Zhao Z, Burkly LC, Campbell S, Schwartz N, Molano A, Choudhury A, Eisenberg RA, Michaelson JS, Putterman C (2007) TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J Immunol 179:7949–7958CrossRefPubMed
19.
Zurück zum Zitat Xuejing Z, Jiazhen T, Jun L, Xiangqing X, Shuguang Y, Fuyou L (2012) Urinary TWEAK level as a marker of lupus nephritis activity in 46 cases. J Biomed Biotechnol 2012:359647CrossRefPubMedPubMedCentral Xuejing Z, Jiazhen T, Jun L, Xiangqing X, Shuguang Y, Fuyou L (2012) Urinary TWEAK level as a marker of lupus nephritis activity in 46 cases. J Biomed Biotechnol 2012:359647CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725CrossRefPubMed Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725CrossRefPubMed
21.
Zurück zum Zitat Bombardier, C, Gladman, DD, Urowitz, MB et al (1992) Derivation of SLEDAI: a disease activity index for lupus patients. Arthritis and Rheumatism. 35:630 Bombardier, C, Gladman, DD, Urowitz, MB et al (1992) Derivation of SLEDAI: a disease activity index for lupus patients. Arthritis and Rheumatism. 35:630
22.
Zurück zum Zitat Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE et al (2004) International Society of Nephrology Working Group on the Classification of Lupus Nephritis and Renal Pathology Society Working Group on the Classification of Lupus Nephritis : Classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65(5):521–530CrossRefPubMed Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE et al (2004) International Society of Nephrology Working Group on the Classification of Lupus Nephritis and Renal Pathology Society Working Group on the Classification of Lupus Nephritis : Classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65(5):521–530CrossRefPubMed
23.
Zurück zum Zitat Bombardier, C, Gladman, DD, Urowitz, MB et al (1992) Derivation of SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 35:630–640 Bombardier, C, Gladman, DD, Urowitz, MB et al (1992) Derivation of SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 35:630–640
24.
Zurück zum Zitat Gladman DD, Ibanez D, Urowitz MB (2002) Systemic lupus erythematosis disease activity index 2000. J Rheumatol 29:288–291 Gladman DD, Ibanez D, Urowitz MB (2002) Systemic lupus erythematosis disease activity index 2000. J Rheumatol 29:288–291
25.
Zurück zum Zitat Schwartz N, Rubinstein T, Burkly LC, Collins CE, Blanco I, Su L, Hojaili B, Mackay M, Aranow C, Stohl W, Rovin BH, Michaelson JS, Putterman C (2009) Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther 11(5):R143CrossRefPubMedPubMedCentral Schwartz N, Rubinstein T, Burkly LC, Collins CE, Blanco I, Su L, Hojaili B, Mackay M, Aranow C, Stohl W, Rovin BH, Michaelson JS, Putterman C (2009) Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther 11(5):R143CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Zhu X, Tan J, Li J, Xu X, Yuan S, Liu F (2012) Urinary TWEAK Level as a marker of Lupus Nephritis activity in 46 cases. J Biomed Biotechnol 2012(359647):1–7 Zhu X, Tan J, Li J, Xu X, Yuan S, Liu F (2012) Urinary TWEAK Level as a marker of Lupus Nephritis activity in 46 cases. J Biomed Biotechnol 2012(359647):1–7
27.
Zurück zum Zitat Pitashny M, Schwartz N, Qing X, Hojaili B, Aranow C, Mackay M, Putterman C (2007) Urinary lipocalin-2 is associated with renal disease activity in human lupus nephritis. Arthritis Rheum 56(6):1894–1903CrossRefPubMed Pitashny M, Schwartz N, Qing X, Hojaili B, Aranow C, Mackay M, Putterman C (2007) Urinary lipocalin-2 is associated with renal disease activity in human lupus nephritis. Arthritis Rheum 56(6):1894–1903CrossRefPubMed
28.
Zurück zum Zitat Marchini M, Antonioli R, Lleo A, Barili M, Caronni M, Origgi L et al (2003) HLA class II antigens associated with lupus nephritis in Italian SLE patients. Hum Immunol 64:462–468CrossRefPubMed Marchini M, Antonioli R, Lleo A, Barili M, Caronni M, Origgi L et al (2003) HLA class II antigens associated with lupus nephritis in Italian SLE patients. Hum Immunol 64:462–468CrossRefPubMed
29.
Zurück zum Zitat Harley JB, Alarcon-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Moser KL et al (2008) Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 40:204–210CrossRefPubMedPubMedCentral Harley JB, Alarcon-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Moser KL et al (2008) Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 40:204–210CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Lee YH, Woo JH, Choi SJ, Ji JD, Song GG (2009) Association of programmed cell death 1 polymorphisms and systemic lupus erythematosus: a meta-analysis. Lupus 18:9–15CrossRefPubMed Lee YH, Woo JH, Choi SJ, Ji JD, Song GG (2009) Association of programmed cell death 1 polymorphisms and systemic lupus erythematosus: a meta-analysis. Lupus 18:9–15CrossRefPubMed
31.
Zurück zum Zitat Gladman DD, Ibanez D, Urowltz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29(2):288–291PubMed Gladman DD, Ibanez D, Urowltz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29(2):288–291PubMed
32.
Zurück zum Zitat Schwartz N, Rubinstein T, Burkly LC et al (2009) Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther 11(5):R143CrossRefPubMedPubMedCentral Schwartz N, Rubinstein T, Burkly LC et al (2009) Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther 11(5):R143CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat El-shehaby A, Darweesh H, El-Khatib M, Momtaz M, Marzouk S, El-Shaarawy N, Emad Y (2011) Correlations of urinary biomarkers, TNF-LikeWeak Inducer of Apoptosis (TWEAK), Osteoprotegerin (OPG), Monocyte Chemoattractant Protein-1 (MCP-1), and IL-8 with lupus nephritis. J Clin Immunol 31(5):848–856CrossRefPubMed El-shehaby A, Darweesh H, El-Khatib M, Momtaz M, Marzouk S, El-Shaarawy N, Emad Y (2011) Correlations of urinary biomarkers, TNF-LikeWeak Inducer of Apoptosis (TWEAK), Osteoprotegerin (OPG), Monocyte Chemoattractant Protein-1 (MCP-1), and IL-8 with lupus nephritis. J Clin Immunol 31(5):848–856CrossRefPubMed
34.
Zurück zum Zitat Schwartz N, Su L, Burkly LC, Mackay M, Aranow C, Kollaros M, Michaelson JS, Rovin B, Putterman C (2006) Urinary TWEAK and the activity of lupus nephritis. J Autoimmun 27(4):242–250CrossRefPubMed Schwartz N, Su L, Burkly LC, Mackay M, Aranow C, Kollaros M, Michaelson JS, Rovin B, Putterman C (2006) Urinary TWEAK and the activity of lupus nephritis. J Autoimmun 27(4):242–250CrossRefPubMed
36.
Zurück zum Zitat Elsayed M, Elhefnawy KA, Qassem AA, Amr GE (2015) Urinary tumor necrosis factor-like weak inducer of apoptosis (tweak) as a marker for lupus nephritis activity. Int J Sci Res 4(2):1615–1619 Elsayed M, Elhefnawy KA, Qassem AA, Amr GE (2015) Urinary tumor necrosis factor-like weak inducer of apoptosis (tweak) as a marker for lupus nephritis activity. Int J Sci Res 4(2):1615–1619
Metadaten
Titel
Urinary TNF-like weak inducer of apoptosis (TWEAK) as a biomarker of lupus nephritis
verfasst von
M. N. Salem
H. A. Taha
M. Abd El-Fattah El-Feqi
N. N. Eesa
R. A. Mohamed
Publikationsdatum
12.09.2016
Verlag
Springer Medizin
Erschienen in
Zeitschrift für Rheumatologie / Ausgabe 1/2018
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI
https://doi.org/10.1007/s00393-016-0184-1

Weitere Artikel der Ausgabe 1/2018

Zeitschrift für Rheumatologie 1/2018 Zur Ausgabe

Mitteilungen der DGRh

Mitteilungen der DGRh

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.